Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

ev3 Expands Neurovascular Division With Acquisition Of Chestnut

This article was originally published in The Gray Sheet

Executive Summary

ev3 is expanding its neurovascular division, already the fastest-growing segment of the company, by buying Chestnut Medical Technologies for $75 million up-front and up to $75 million in milestone payments, the companies announced June 2

You may also be interested in...



Covidien’s Pipeline, NovoCure’s NovoTFF Set For FDA Panel Review

FDA’s Neurological Devices panel is set to review Covidien’s Pipeline embolization device and NovoCure’s NovoTFF-100A brain tumor treatment kit during a March 17-18 meeting.

Covidien’s Pipeline, NovoCure’s NovoTFF Set For FDA Panel Review

FDA’s Neurological Devices panel is set to review Covidien’s Pipeline embolization device and NovoCure’s NovoTFF-100A brain tumor treatment kit during a March 17-18 meeting.

Covidien Runs Familiar But Different Plays to Build Vascular Franchise

Covidien Ltd. continues to build its vascular global business unit with the acquisition of peripheral leader ev3 Inc.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

MT027522

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel